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THE EFFECT OF RIVASTIGMINE ON THE 
DIRECT AND INDIRECT COSTS OF 
ALZHEIMER’S DISEASE
Brooks E, Deal L
Research Triangle Institute, Center for Economics Research, 
Research Triangle Park, NC, USA
A recent study used data from two Phase III clinical trials of
rivastigmine efficacy and safety to model rivastigmine’s ef-
fect on the progression of Alzheimer’s disease (AD). In these
trials, a patient’s AD status is gauged by measuring cog-
nitive function using the mini-mental state exam (MMSE).
The hazard model developed in this study has been used
to estimate disease stage-specific savings in direct cost of
caring for AD patients resulting from treatment with ri-
vastigmine. OBJECTIVES: We refined this model to esti-
mate precise MMSE score-specific savings and investigate
the distribution of cost savings across direct and indirect
costs of caring for AD patients. METHODS: MMSE score-
specific estimates of AD progression in both untreated and
treated patients were combined with both MMSE score-
specific estimates of direct and indirect costs of AD, and
estimates of the probability of institutionalization from
previous studies. We estimated potential savings due to
rivastigmine treatment in direct, indirect, and total costs
of caring for AD patients in the US. We analyzed the rel-
ative magnitudes of these cost savings across MMSE
scores for three treatment time horizons. RESULTS: As a
percentage of total gross cost savings, savings in indirect
costs are greatest for both mild and moderate patients
during the first 6 months of treatment. After 2 years of
treatment, gross direct cost savings make up the majority
of overall cost savings for both mild and moderate pa-
tients. CONCLUSIONS: Decreases in likelihood of insti-
tutionalization resulting from treatment appear to be
driving these results. Results clearly demonstrate long-
term savings of early initiation of rivastigmine treatment.
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OBJECTIVES: The study purpose was to evaluate cost-
effectiveness for the treatment with some depot neurolep-
tics (decanoate zuclopenthixol, decanoate flupenthixol,
palmitate pipothiasine) for patients with schizophrenia
(ICD-10) in a Moscow community psychiatric outpatient
clinic compared with oral forms of conventional neuro-
leptics. METHODS: In the frame of the first (clinical)
stage a 24-week mirror-image cost-effectiveness study
was performed. Three cohorts of 34, 29 and 29 patients
at high risk of relapse or frequent exacerbation of schizo-
phrenic symptoms and consequent hospitalization were
treated with decanoate zuclopenthixol, decanoate flu-
penthixol, palmitate pipothiasine, respectively. Clinical
improvement was evaluated with PANSS  CGI, and dy-
namic of social functioning and quality of life of patients
with original checklist. Severity of extrapyramidal side
effects was evaluated with Simpson-Angus scale. Cost
analysis was performed including relevant data about the
direct and indirect costs (rub. 1998) for all of the pa-
tients. At the second (analytic) study stage by means of
decision tree simulation model an economic evaluation of
treatment with the depot neuroleptics over a hypothetical
five-year period was performed. RESULTS: Statistically
significant clinical improvement along with improvement
of social functioning and quality of life of all of the pa-
tients receiving depot were achieved. Economic analysis
indicated significant (50%) saving in the total medical
cost associated with the patients despite the fact that
these medicines have a higher acquisition cost. Twice as
much gain was achieved from the societal perspective.
Analytic method confirms that long-term treatment with
the depot antipsychotics is cost-effective versus standard
oral ones. CONCLUSIONS: The treatment of schizo-
phrenia with studied Depot neuroleptics should be con-
sidered as an evidence based (first line) maintenance
strategy in usual practice setting especially for outpa-
tients with problems of compliance.
PMH7
COST-EFFECTIVENESS OF ATYPICAL 
ANTIPSYCHOTICS IN CHRONIC 
SCHIZOPHRENIA
Karki SD1, Bellnier TJ1, Hager EP2
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Atypical antipsychotics have equal or better clinical effi-
cacy and more favorable side effect profiles when com-
pared with typical antipsychotics and are increasingly
prescribed. Cost-effectiveness approach will guide the in-
stitutions to optimize the limited medication budget. OB-
JECTIVE: The purpose of this study is to compare the
cost-effectiveness of three atypical antipsychotics; cloza-
pine, risperidone and olanzapine. METHODS: Patients,
treatment refractory to conventional antipsychotics, were
started on clozapine or risperidone or olanzapine in an
open-label, prospective effectiveness and safety evalua-
tion. Subjects from each treatment group were matched
for age, sex, ethnicity, diagnosis, current length of hospi-
talization and baseline BPRS scores. Samples of 50 pa-
tients were randomly selected from each effectiveness and
safety evaluation to compare cost-effectiveness by using
the change in BPRS score after six months of treatment.
RESULTS: BPRS scores were 61, 59, and 59 at baseline
and 42, 54 and 42 for clozapine, risperidone and olanza-
pine at the end of six months. Average prescriptions costs
u
